Research Study

A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Principal Investigator 
Stephen Chia

Overview

Body Locations and Systems 
Breast Cancer
Disorders and Conditions 
Breast Cancer
ClinicalTrials.gov# 
NCT01966471
Status 
Closed to Recruitment
Study Start/End 
Jan 7, 2014 to Dec 31, 2014
Locations 
St. Paul's Hospital, Vancouver General Hospital
Name/Title 
Janice Pope, Study Coordinator
Phone 
604-877-6000 ext.2329
Email Address 
jpope@bccancer.bc.ca
Purpose of Study 

This two-arm, randomized, open-label, multicenter study will evaluate the effica cy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combina tion with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination wit h Perjeta and a taxane as adjuvant therapy in patients with HER2-positive primar y invasive breast cancer. Following surgery and anthracycline-based chemotherapy, patients will receive either Kadcyla 3.6 mg/kg and Perjeta 420 mg intravenousl y (iv) every three weeks or Herceptin 6 mg/kg iv every three weeks in combinatio n with Perjeta and a taxane. Anticipated time on HER2 targeted study treatment i s up to 1 year.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.